Pune Magazine

According to DelveInsight, the Chronic Obstructive Pulmonary Disease Market in 7MM is expected to witness a major change in the study period 2019-2032

 Breaking News
  • No posts were found

According to DelveInsight, the Chronic Obstructive Pulmonary Disease Market in 7MM is expected to witness a major change in the study period 2019-2032

September 16
04:21 2022
According to DelveInsight, the Chronic Obstructive Pulmonary Disease Market in 7MM is expected to witness a major change in the study period 2019-2032

“The increase in Chronic Obstructive Pulmonary Disease Market size is a direct consequence of an increase in R& D activity, increasing prevalent population, expected commercial success of upcoming therapies in the 7MM

 

The Chronic Obstructive Pulmonary Disease Market is expected to gain market growth in the forecast period of 2022 to 2032. The growing cases of tumors will directly impact the growth of the Chronic Obstructive Pulmonary Disease Market

 

The Chronic Obstructive Pulmonary Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Obstructive Pulmonary Disease market size from 2019 to 2032. The Report also covers current Chronic Obstructive Pulmonary Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Key takeaways from the Chronic Obstructive Pulmonary Disease Market Research Report

  • The expected launch of the Chronic Obstructive Pulmonary Disease emerging therapies and the research and development activities of pharmaceutical companies will also fuel the Chronic Obstructive Pulmonary Disease market growth during the forecast period.
  • The estimates suggest a Chronic Obstructive Pulmonary Disease higher diagnosed prevalence in the United States with 17,455,605 diagnosed cases in 2020, which might increase in 2030.
  • The total Chronic Obstructive Pulmonary Disease diagnosed prevalent population in seven major markets was found to be 31,730,590 in 2020 and is anticipated to increase in 2030.
  • Chronic Obstructive Pulmonary Disease Market Companies included Afimmune, AstraZeneca, Amgen, Circassia Pharmaceuticals Inc., Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Chiesi Farmaceutici S.p.A., Genentech, GlaxoSmithKline, and several others
  • Chronic Obstructive Pulmonary Disease Market Therapies included Anoro Ellipta, Incruse Ellipta/Encruse Ellipta, and several others

 

Interested to know more about the ongoing developments in the Chronic Obstructive Pulmonary Disease Market Outlook? Visit here- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

 

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The most common respiratory symptoms include dyspnea, cough, and/or sputum production; these symptoms may be under-reported by patients. The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute.

Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging. COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations. In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality. COPD is a long-lasting lung disease where the small airways in the lungs are damaged, making it harder for air to get in and out.

 

Chronic Obstructive Pulmonary Disease Epidemiology Insights

The Chronic Obstructive Pulmonary Disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM 

  • Total Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases
  • Chronic Obstructive Pulmonary Disease Gender-specific Diagnosed Prevalent Cases
  • Chronic Obstructive Pulmonary Disease Age-specific Diagnosed Prevalent Cases
  • Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases Based on Severity of Airflow Limitation

 

Chronic Obstructive Pulmonary Disease Treatment Market

Chronic Obstructive Pulmonary Disease treatment include drugs, for example, nicotine replacement therapy, beta-2 agonists and anticholinergic agents (bronchodilators), combined drugs using steroids and long-acting bronchodilators, mucolytic agents, oxygen therapy, and surgical procedures such as bullectomy, lung volume reduction surgery, and lung transplantation. The goals of COPD treatment are to reduce hospitalizations, reduce and prevent exacerbations, decrease dyspnea, improve quality of life, slow disease progression, and reduce mortality. The mainstays of treatment are smoking cessation, when applicable, and pharmacotherapy with inhaled bronchodilators and corticosteroids. Additional therapies include oral phosphodiesterase-4 inhibitors, vaccinations, pulmonary rehabilitation, and long-term oxygen therapy in hypoxic patients. Bronchodilators are used to treat chronic obstructive pulmonary disease (COPD). The medicines come in many forms, with some forms requiring special instructions. There are several short-acting bronchodilators for COPD.

 

Discover more relevant information on the Chronic Obstructive Pulmonary Disease Market Research Report here- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

 

Chronic Obstructive Pulmonary Disease Marketed Drugs

Anoro Ellipta: GlaxoSmithKline/Theravance/Innoviva

Anoro Ellipta is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) (FDA, 2013). Anoro Ellipta is a once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of COPD.

Incruse Ellipta/Encruse Ellipta: GlaxoSmithKline

Incruse Ellipta is an anticholinergic approved for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. GSK’s once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist (LAMA), is contained in the Ellipta inhaler. The FDA-approved strength is 62.5 mcg.

 

Chronic Obstructive Pulmonary Disease Emerging Drugs

Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role.

Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response (Sastre, 2018). Dupilumab is approved in the US to treat patients aged ≥12 with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies.

 

Chronic Obstructive Pulmonary Disease Market Outlook

Many people with Chronic Obstructive Pulmonary Disease have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal in treating Chronic Obstructive Pulmonary Disease is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. Chronic Obstructive Pulmonary Disease treatment focuses on relieving symptoms, such as coughing, breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of Chronic Obstructive Pulmonary Disease.

 

Chronic Obstructive Pulmonary Disease Market Size

The Chronic Obstructive Pulmonary Disease Market Size has been categorized into three groups based on the type of therapies that are used and that might get launched, i.e., Monotherapies, Double combination therapies, and Triple combination therapies. The monotherapies are further categorized into Long-Acting Bronchodilators (LABDs), Inhaled Corticosteroids (ICS), Phosphodiesterase Type 4 Inhibitors, and other monotherapies. In LABA, drugs like Striverdi Respimat, Arcapta/Onbrez, Serevent, and Brovana are there, and in LAMA class, molecules such as Spiriva (Spiriva HandiHaler and Spiriva Respimat), Tudorza Pressair, Incruse Ellipta, Yupelri, Seebri Neohaler, Lonhala Magnair, etc. are included.

 

Read more about the Chronic Obstructive Pulmonary Disease Market Companies and Therapies in the report- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

 

Scope of the Chronic Obstructive Pulmonary Disease Market Forecast Report

  • Coverage- 7MM
  • Study Period-2019-2032
  • Chronic Obstructive Pulmonary Disease Market Forecast Period- 2022-2032
  • Chronic Obstructive Pulmonary Disease Market Companies included Afimmune, AstraZeneca, Amgen, Circassia Pharmaceuticals Inc., Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Chiesi Farmaceutici S.p.A., Genentech, GlaxoSmithKline, and several others
  • Chronic Obstructive Pulmonary Disease Market Therapies included Anoro Ellipta, Incruse Ellipta/Encruse Ellipta, and several others
  • Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
  • KOL Views
  • Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance

4. Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Organizations contributing toward Chronic Obstructive Pulmonary Disease (COPD)

10. Chronic Obstructive Pulmonary Disease Marketed Therapies

11. Chronic Obstructive Pulmonary Disease Emerging Drugs

12. Potential of Emerging and Current therapies

13. Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis

14. KOL Views

15. Chronic Obstructive Pulmonary Disease Market Drivers

16. Chronic Obstructive Pulmonary Disease Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Reimbursement and Chronic Obstructive Pulmonary Disease Market Access

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Got queries? Reach out for more details on the Chronic Obstructive Pulmonary Disease Market Forecast Report- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories